JP2003526595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003526595A5 JP2003526595A5 JP2000507359A JP2000507359A JP2003526595A5 JP 2003526595 A5 JP2003526595 A5 JP 2003526595A5 JP 2000507359 A JP2000507359 A JP 2000507359A JP 2000507359 A JP2000507359 A JP 2000507359A JP 2003526595 A5 JP2003526595 A5 JP 2003526595A5
- Authority
- JP
- Japan
- Prior art keywords
- eczema
- pharmaceutical composition
- composition according
- active ingredient
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004624 Dermatitis Diseases 0.000 claims 23
- 208000010668 atopic eczema Diseases 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000004480 active ingredient Substances 0.000 claims 9
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 6
- 229960001445 alitretinoin Drugs 0.000 claims 6
- 230000003902 lesion Effects 0.000 claims 5
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 4
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- -1 sachet Substances 0.000 claims 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 4
- 210000002374 sebum Anatomy 0.000 claims 4
- 208000001875 irritant dermatitis Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 210000004243 sweat Anatomy 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010093 eczematous lesion Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97114651A EP0908179A1 (en) | 1997-08-23 | 1997-08-23 | Treatment of cell-mediated immune diseases |
| EP97114651.9 | 1997-08-23 | ||
| PCT/EP1998/005236 WO1999009969A1 (en) | 1997-08-23 | 1998-08-18 | Treatment of cell-mediated immune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003526595A JP2003526595A (ja) | 2003-09-09 |
| JP3522220B2 JP3522220B2 (ja) | 2004-04-26 |
| JP2003526595A5 true JP2003526595A5 (enExample) | 2005-04-07 |
Family
ID=8227266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000507359A Expired - Lifetime JP3522220B2 (ja) | 1997-08-23 | 1998-08-18 | 細胞媒介性免疫病の処置 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6589989B1 (enExample) |
| EP (2) | EP0908179A1 (enExample) |
| JP (1) | JP3522220B2 (enExample) |
| KR (1) | KR100596260B1 (enExample) |
| CN (1) | CN1136845C (enExample) |
| AT (1) | ATE259224T1 (enExample) |
| AU (1) | AU739440B2 (enExample) |
| BR (1) | BRPI9811989B8 (enExample) |
| CA (1) | CA2301907C (enExample) |
| DE (1) | DE69821624T2 (enExample) |
| DK (1) | DK1007020T3 (enExample) |
| ES (1) | ES2214729T3 (enExample) |
| NO (1) | NO327141B1 (enExample) |
| NZ (1) | NZ502812A (enExample) |
| PT (1) | PT1007020E (enExample) |
| RU (1) | RU2238083C2 (enExample) |
| TR (1) | TR200000488T2 (enExample) |
| WO (1) | WO1999009969A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541469B2 (en) * | 1997-08-23 | 2013-09-24 | Glaxo Group Limited | Treatment of cell-mediated immune diseases |
| US20020031539A1 (en) * | 2000-08-30 | 2002-03-14 | The Brigham And Women's Hospital, Inc. | Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
| DE10255861A1 (de) * | 2002-11-29 | 2004-06-17 | Axxima Pharmaceuticals Ag | Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen |
| FR2834216B1 (fr) * | 2001-12-27 | 2004-04-30 | Pharmascience Lab | Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations |
| JP2004020220A (ja) * | 2002-06-12 | 2004-01-22 | Pioneer Electronic Corp | 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム |
| TW579640B (en) * | 2002-10-23 | 2004-03-11 | Veutron Corp | Light gathering device of scanner |
| EP1527774A1 (en) * | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
| EP2327401A3 (en) * | 2003-03-14 | 2011-10-19 | University of Washington | Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof |
| ES2449494T3 (es) | 2003-04-11 | 2014-03-20 | Glaxo Group Limited | Procedimiento para la producción de ácido 9-cis-retinoico |
| US7122751B1 (en) * | 2004-01-16 | 2006-10-17 | Cobalt Flux | Switch apparatus |
| CN1921843A (zh) * | 2004-01-23 | 2007-02-28 | 独立行政法人科学技术振兴机构 | 含视黄酸的糖尿病治疗药 |
| AU2015207903B2 (en) * | 2004-06-18 | 2017-08-17 | University Of Washington | Retinal derivatives and methods for the use thereof for the treatment of visual disorders |
| JP5166026B2 (ja) | 2004-06-18 | 2013-03-21 | ユニバーシティ オブ ワシントン | 視力障害の治療のためのレチナール誘導体およびその使用方法 |
| AU2012216808B2 (en) * | 2004-06-18 | 2015-04-30 | University Of Washington | Retinal derivatives and methods for the use thereof for the treatment of visual disorders |
| CN101262861B (zh) * | 2005-09-09 | 2011-04-06 | 有限会社肯菲思 | 用于预防及/或治疗肠疾病的药物 |
| JP6022746B2 (ja) | 2008-02-11 | 2016-11-09 | ユニヴァーシティ オブ ワシントン | 加齢関連性網膜機能不全の治療及び予防方法 |
| US8580278B2 (en) * | 2009-06-03 | 2013-11-12 | Trustees Of Dartmouth College | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| JP5663025B2 (ja) | 2009-09-15 | 2015-02-04 | キューエルティー インコーポレイテッド | ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤 |
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| CA2796991A1 (en) | 2010-04-19 | 2011-10-27 | Qlt Inc. | Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| CN102247348A (zh) * | 2011-05-23 | 2011-11-23 | 天津拓飞生物科技有限公司 | 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用 |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| WO2013009945A1 (en) | 2011-07-12 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
| MX370928B (es) | 2012-03-01 | 2020-01-08 | Retinagenix LLC | El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal. |
| EP2858648B1 (en) | 2012-06-07 | 2018-08-22 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of pin1 |
| US9221854B2 (en) | 2012-08-17 | 2015-12-29 | Basf Se | Isomerization of olefinic compounds |
| KR102138561B1 (ko) | 2012-08-17 | 2020-07-28 | 바스프 에스이 | 올레핀계 화합물의 이성질화 |
| US20150202172A1 (en) * | 2014-01-22 | 2015-07-23 | Glaxo Group Limited | Novel method of use |
| US9968579B2 (en) | 2014-07-17 | 2018-05-15 | Beth Isreal Deaconess Medical Center, Inc. | ATRA for modulating Pin1 activity and stability |
| WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
| WO2016145186A1 (en) | 2015-03-12 | 2016-09-15 | Beth Israel Deaconess Medical Center, Inc. | Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| CA2997211A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
| CA3030974A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| CN113499335B (zh) * | 2021-07-13 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向自噬融合治疗神经退行性疾病的药物 |
| WO2025108208A1 (zh) * | 2023-11-21 | 2025-05-30 | 南京纽邦生物科技有限公司 | 用于改善或维持皮肤、毛囊、头皮或毛发健康的方法和组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525635A (en) * | 1986-02-04 | 1996-06-11 | Moberg; Sven | Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof |
| US5093360A (en) * | 1989-04-07 | 1992-03-03 | Yu Ruey J | Retinal, derivatives and their therapeutic use |
| US5057501A (en) * | 1990-03-13 | 1991-10-15 | Dermatologic Research Corporation | Methods for treatment of papulosquamous and eczematous diseases |
| US5932622A (en) * | 1991-12-18 | 1999-08-03 | The Salk Institute For Biological Studies | Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid |
| KR100274101B1 (ko) | 1992-01-22 | 2000-12-15 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 9-시스 레틴산을 함유하는 약제학적 조성물 |
| US5750570A (en) * | 1992-03-31 | 1998-05-12 | The Regents Of The University Of Michigan | Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid |
| CA2093577C (en) | 1992-05-07 | 2006-01-03 | Michael Klaus | Alkyl or alkoxy substituted s-heterocyclic retinoids |
| TW272187B (enExample) * | 1992-05-20 | 1996-03-11 | Hoffmann La Roche | |
| WO1994022818A1 (en) * | 1993-04-05 | 1994-10-13 | Pfizer Inc. | Method for the preparation of 9-cis retinoic acid |
| US5457129A (en) * | 1993-05-17 | 1995-10-10 | Research Development Foundation | Inhibition of nitric oxide production by retinoic acid |
| FR2717686B1 (fr) * | 1994-03-22 | 1996-06-28 | Fabre Pierre Cosmetique | Composition dermo-cosmétologique et procédé de préparation. |
| DE4415204A1 (de) * | 1994-04-30 | 1995-11-02 | Carl Heinrich Dr Weischer | Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika |
| FR2728790B1 (fr) * | 1994-12-29 | 1997-01-24 | Cird Galderma | Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial |
| US6083977A (en) * | 1994-12-30 | 2000-07-04 | Ligand Pharmaceuticals Incorporated | Trienoic retinoid compounds and methods |
| US5837728A (en) * | 1995-01-27 | 1998-11-17 | Molecular Design International | 9-cis retinoic acid esters and amides and uses thereof |
| FR2735367B1 (fr) * | 1995-06-19 | 1997-07-18 | Cird Galderma | Utilisation de ligands specifiques des recepteurs rxrs |
| FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
| US5994081A (en) * | 1998-04-27 | 1999-11-30 | Incyte Pharamaceuticals, Inc. | Human keratins |
| US20030105031A1 (en) * | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Methods for the treatment of skin disorders |
-
1997
- 1997-08-23 EP EP97114651A patent/EP0908179A1/en not_active Withdrawn
-
1998
- 1998-08-18 CN CNB98808743XA patent/CN1136845C/zh not_active Expired - Lifetime
- 1998-08-18 DE DE69821624T patent/DE69821624T2/de not_active Expired - Lifetime
- 1998-08-18 RU RU2000107124/14A patent/RU2238083C2/ru active
- 1998-08-18 KR KR1020007001813A patent/KR100596260B1/ko not_active Expired - Lifetime
- 1998-08-18 WO PCT/EP1998/005236 patent/WO1999009969A1/en not_active Ceased
- 1998-08-18 BR BRPI9811989A patent/BRPI9811989B8/pt not_active IP Right Cessation
- 1998-08-18 CA CA002301907A patent/CA2301907C/en not_active Expired - Lifetime
- 1998-08-18 PT PT98947437T patent/PT1007020E/pt unknown
- 1998-08-18 AU AU94356/98A patent/AU739440B2/en not_active Expired
- 1998-08-18 DK DK98947437T patent/DK1007020T3/da active
- 1998-08-18 NZ NZ502812A patent/NZ502812A/en not_active IP Right Cessation
- 1998-08-18 TR TR2000/00488T patent/TR200000488T2/xx unknown
- 1998-08-18 ES ES98947437T patent/ES2214729T3/es not_active Expired - Lifetime
- 1998-08-18 EP EP98947437A patent/EP1007020B1/en not_active Expired - Lifetime
- 1998-08-18 US US09/485,943 patent/US6589989B1/en not_active Expired - Lifetime
- 1998-08-18 JP JP2000507359A patent/JP3522220B2/ja not_active Expired - Lifetime
- 1998-08-18 AT AT98947437T patent/ATE259224T1/de active
-
2000
- 2000-02-22 NO NO20000870A patent/NO327141B1/no not_active IP Right Cessation
-
2003
- 2003-06-11 US US10/459,273 patent/US20040039056A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003526595A5 (enExample) | ||
| US5292772A (en) | Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome | |
| ES2244103T3 (es) | Remedio para enfermedades neurodegenerativas. | |
| RU2000107124A (ru) | Лечение опосредуемых клеткой иммунных болезней | |
| CA1198057A (en) | Method of contraception using peak progestogen dosage | |
| US4978680A (en) | Method for the prevention and control of epileptic seizure | |
| US5206029A (en) | Medicament and its production and use in the treatment of pain, inflammation and fever in man and animals | |
| JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
| US6025394A (en) | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | |
| JP2009102342A5 (enExample) | ||
| CA2307879A1 (en) | Treatment of t-helper cell type 2 mediated immune diseases | |
| JP2003508441A5 (enExample) | ||
| CA2470703A1 (en) | Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation | |
| JPS6352015B2 (enExample) | ||
| JPH03206064A (ja) | 速効性かつ鎮痛効果が増強された鎮痛剤としてのｓ（＋）―イブプロフエン―ｌ―アミノ酸とｓ（＋）―イブプロフエン―ｄ―アミノ酸 | |
| EP0228253A1 (en) | Rectally absorbable form of L-dopa | |
| WO2009069139A1 (en) | Dosage form providing an ibuprofen-containing liquid fill | |
| AU740875B2 (en) | Novel use of compounds for anti-pruritic activity | |
| US5702723A (en) | Multi-stage delivery system for ingestible medications or nutrients | |
| JP3122748B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
| JPS605580B2 (ja) | 新ナフタレン誘導体の製法 | |
| AU616755B2 (en) | Topically applied gold organic complex | |
| JP2834512B2 (ja) | リポキシン誘導体を有効成分とする疾患治療剤 | |
| US20080021083A1 (en) | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance | |
| US20080268022A1 (en) | Mehtods for treating and preventing ailments caused by human papillomavirus |